

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

CHANGE IN ACCOUNTING POLICY

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) and Rule 13.10B of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

I. INTRODUCTION

Through its unique CRDMO (Contract Research Development and Manufacturing Organization) business model, the Company continues to lower the barrier for research and development (R&D), and helping customers increase the efficiency of R&D so as to deliver more groundbreaking treatments to patients. The service scope of CRDMO covers chemical drug R&D and production, biology discovery, preclinical testing and clinical research services. In order to provide more focused and relevant accounting information in the financial reports to reflect the Group's current main businesses and growth drivers, the Company has decided to make changes in its accounting policies and adjust the way in which the reportable segments are divided (the “**Change in Accounting Policy**”).

The Company held the seventeenth meeting of the third session of the Board on March 17, 2025, at which the Change in Accounting Policy was considered and approved.

II. DETAILS OF AND REASONS FOR THE CHANGE IN ACCOUNTING POLICY

Prior to the Change in Accounting Policy, the Group's reportable segments are primarily divided into WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU and Others. After the Change in Accounting Policy, the continuing operations are primarily divided into WuXi Chemistry, WuXi Testing, WuXi Biology and Others.

Following the Change in Accounting Policy, the reportable segments are primarily divided into:

- (1) WuXi Chemistry: Providing services for chemistry drug development from discovery, through preclinical and clinical stages, to commercial manufacturing, offering an integrated, end-to-end solution, meeting any material requirement at any scale, covering all categories for all synthetic molecular modalities, including small molecules, oligonucleotides, peptides and related chemistry conjugates, as well as supporting the formulation business for various chemical drugs.
- (2) WuXi Testing: Providing seamless drug testing services from preclinical testing to clinical trials, covering laboratory testing service, clinical contract research organization service, and site management organization service, accelerating the research and development process.
- (3) WuXi Biology: Providing a full spectrum of biology services and solutions that support various biological research and testing projects, from target discovery to candidate selection and optimization, and into the clinic, for different target classes and molecular types.
- (4) Others: Comprising the non-core business, as well as income from administrative services, sales of raw materials and sales of scrap materials.

III. IMPACT OF THE CHANGE IN ACCOUNTING POLICY

(I) Requirements of the accounting standards

The Change in Accounting Policy is made in accordance with the relevant provisions of Article 8 and Article 9 of the “Accounting Standards for Business Enterprises No. 35 — Segment Reporting” and “Interpretation of Accounting Standards for Business Enterprises No. 3”, as well as the requirements of the Company’s internal management. From the fourth quarter of 2024 onwards, in order to enhance the quality of information disclosure and provide more relevant segmental financial information for users of financial statements, the Company has decided that WuXi Chemistry, WuXi Testing, WuXi Biology and Others shall be the new format of the disclosure of segmental information in financial reports.

(II) Impact

The Change in Accounting Policy only affects the presentation of segmental information in the notes to the financial reports and does not affect the data of the financial statements of the Company such as total assets, total liabilities, net assets and net profit. According to the Accounting Standards for Business Enterprises (“ASBE”) the Company has prepared segmental information for the 2024 annual results announcement and 2024 annual report based on the adjusted presentation of reporting segments from the fourth quarter of 2024 onwards, and has restated the data for the corresponding period in 2023. The Company believes that the new format of disclosure is more in line with the actual and current conditions of the business operations of the Group, and can help investors better understand and analyze the operation performance of the Group, as well as to put their focuses on the Company’s main businesses and growth points.

IV. OPINIONS OF THE SUPERVISORY COMMITTEE AND AUDITOR

The supervisory committee of the Company (the “**Supervisory Committee**”) is of the view that: (i) the Change in Accounting Policy is in compliance with laws, regulations and relevant documents of the Ministry of Finance; and (ii) the decision-making procedures are in compliance with relevant laws, regulations and the articles of association of the Company (the “**Articles of Association**”). As such, the Supervisory Committee agreed to the Change in Accounting Policy, and the Change in Accounting Policy shall be implemented with effect from the fourth quarter of 2024.

The auditor of the Company, Deloitte Touche Tohmatsu Certified Public Accountants LLP, issued the special explanation on the Change in Accounting Policy that Deloitte Touche Tohmatsu Certified Public Accountants LLP, as an accounting firm, examined the information set out in the Special Explanation on the Change in Accounting Policy by the Board of Directors of WuXi AppTec Co., Ltd.* (《無錫藥明康德新藥開發股份有限公司董事會關於會計政策變更的專項說明》) and did not identify any non-compliance with the ASBE in all material respects.

V. OPINION OF THE AUDIT COMMITTEE OF THE COMPANY

The audit committee of the Company (the “**Audit Committee**”) has considered and approved the Change in Accounting Policy, and is of the view that: (i) the Change in Accounting Policy is in compliance with laws, regulations and relevant documents of the Ministry of Finance; and (ii) the decision-making procedures are in compliance with relevant laws, regulations and the Articles of Association; and (iii) the Change in Accounting Policy can objectively and fairly reflect the current financial position and results of operations of the Company; and (iv) the Change in Accounting Policy is in line with the interests of the Company and the Shareholders. As such, the Audit Committee agreed to the Change in Accounting Policy, and the Change in Accounting Policy shall be implemented with effect from the fourth quarter of 2024.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, March 17, 2025

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*